Actively Recruiting
A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis in Patients With Lower Respiratory Tract Infection in ICU
Led by Ain Shams University · Updated on 2025-07-28
160
Participants Needed
1
Research Sites
11 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate and compare the ability of two blood test ratios, the Neutrophil/Lymphocyte ratio (NLR) and the Lactate/Albumin ratio (L/A ratio), to predict outcomes in patients with sepsis and septic shock caused by lower respiratory tract infections. Sepsis is a serious condition where the body's response to infection causes organ dysfunction and can be life-threatening, especially in intensive care settings. The study focuses on understanding which ratio better predicts patient prognosis and mortality. Participants admitted to the intensive care unit with sepsis related to lower respiratory infections will undergo clinical assessments and laboratory tests. Data collected include demographics, vital signs, medication use, mental status, and organ function scores. Blood tests will measure neutrophils, lymphocytes, serum albumin, lactate, and other markers. Various body fluid cultures will be taken to identify infection sources. All tests are performed at a central lab. During the study, researchers will track patient outcomes such as mortality, length of ICU stay, use of vasoactive medications, and support therapies like mechanical ventilation or renal replacement. The main outcomes are mortality and the prognostic value of the two blood test ratios measured from ICU admission until discharge or death. The study will last 12 to 18 months, with careful monitoring to understand how these ratios relate to patient survival and recovery.
CONDITIONS
Brief Title
A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with lower respiratory tract infection
- Confirmed sepsis diagnosis under Sepsis-3 definitions
- Admitted to intensive care unit
- Age between 18 and 80 years
- Both genders
You will not qualify if you...
- Age under 18 or over 80 years
- Patient refusal to participate
- Pregnancy
- Malignancy
- Conditions affecting serum albumin before ICU admission, including malnutrition, nephrotic syndrome, liver cirrhosis, or intestinal resection surgeries
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) at ICU admission for eligibility assessment
Duration - At ICU admission
Participants undergo clinical, laboratory, and microbiological evaluations upon ICU admission to assess inflammatory markers and sepsis status.
1 visit (in-person) for clinical and laboratory investigations
Duration - Up to 12 to 18 months
Participants are monitored during their ICU stay to track mortality, length of stay, and need for supportive therapies.
Continuous monitoring during ICU stay with data collected until discharge or death
Trial Site Locations
Total: 1 location
1
Ain Shams university
Cairo, Abbassia, Egypt, 00202
Actively Recruiting
Research Team
A
Ahmed Gamal Ahmed, M.BB.CH,M.Sc
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here